Private Trust Co. NA lifted its position in Amgen, Inc. (NASDAQ:AMGN) by 6.3% in the 4th quarter, HoldingsChannel reports. The fund owned 7,339 shares of the medical research company’s stock after buying an additional 433 shares during the period. Private Trust Co. NA’s holdings in Amgen were worth $1,276,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. Toronto Dominion Bank lifted its position in shares of Amgen by 11.0% in the 3rd quarter. Toronto Dominion Bank now owns 279,280 shares of the medical research company’s stock valued at $52,066,000 after acquiring an additional 27,726 shares in the last quarter. Welch Group LLC purchased a new stake in shares of Amgen in the 2nd quarter valued at approximately $639,000. DekaBank Deutsche Girozentrale lifted its position in shares of Amgen by 2.8% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 883,579 shares of the medical research company’s stock valued at $152,927,000 after acquiring an additional 24,219 shares in the last quarter. Pacer Advisors Inc. lifted its position in shares of Amgen by 10.3% in the 2nd quarter. Pacer Advisors Inc. now owns 25,378 shares of the medical research company’s stock valued at $4,371,000 after acquiring an additional 2,362 shares in the last quarter. Finally, Teacher Retirement System of Texas lifted its position in shares of Amgen by 16.5% in the 3rd quarter. Teacher Retirement System of Texas now owns 740,764 shares of the medical research company’s stock valued at $138,115,000 after acquiring an additional 104,871 shares in the last quarter. Institutional investors and hedge funds own 78.03% of the company’s stock.
In other news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $176.83, for a total transaction of $269,665.75. Following the transaction, the executive vice president now owns 56,106 shares in the company, valued at approximately $9,921,223.98. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last 90 days, insiders have sold 4,575 shares of company stock worth $818,361. 0.19% of the stock is currently owned by company insiders.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $3.03 by ($0.14). Amgen had a return on equity of 30.87% and a net margin of 8.66%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.84 billion. During the same quarter last year, the company earned $2.89 EPS. The business’s revenue for the quarter was down 2.7% compared to the same quarter last year. research analysts forecast that Amgen, Inc. will post 13.21 earnings per share for the current year.
Amgen declared that its board has initiated a share repurchase plan on Wednesday, October 25th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to repurchase shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s management believes its stock is undervalued.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be paid a dividend of $1.32 per share. This is a positive change from Amgen’s previous quarterly dividend of $1.15. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $5.28 annualized dividend and a dividend yield of 2.88%. Amgen’s dividend payout ratio is 205.45%.
A number of research firms have issued reports on AMGN. Leerink Swann reiterated a “market perform” rating on shares of Amgen in a research report on Friday, February 2nd. Atlantic Securities downgraded shares of Amgen from an “overweight” rating to a “neutral” rating and set a $187.01 target price for the company. in a research report on Monday, February 5th. Royal Bank of Canada cut their target price on shares of Amgen from $192.00 to $188.00 and set a “sector perform” rating for the company in a research report on Thursday, October 26th. Oppenheimer set a $205.00 target price on shares of Amgen and gave the stock a “buy” rating in a research report on Friday, January 5th. Finally, BidaskClub upgraded shares of Amgen from a “sell” rating to a “hold” rating in a research report on Thursday, January 18th. Sixteen analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $191.84.
TRADEMARK VIOLATION WARNING: “Amgen, Inc. (AMGN) Shares Bought by Private Trust Co. NA” was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.com-unik.info/2018/02/20/amgen-inc-amgn-shares-bought-by-private-trust-co-na.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.